BIOMARIN PHARMACEUTICAL INC (BMRN)

US09061G1013 - Common Stock

89.25  -1.12 (-1.24%)

After market: 89.25 0 (0%)

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (9/28/2023, 7:00:00 PM)

After market: 89.25 0 (0%)

89.25

-1.12 (-1.24%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)07-31 2023-07-31/amc
Earnings (Next)10-24 2023-10-24/amc
Ins Owners0.67%
Inst Owners94.56%
Market Cap16.79B
Shares188.18M
PE171.63
Fwd PE34.89
Dividend YieldN/A
Analysts78.75
IPO07-23 1999-07-23
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMRN Daily chart

Company Profile

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,082 full-time employees. The firm's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Company Info

BIOMARIN PHARMACEUTICAL INC

105 Digital Dr

Novato CALIFORNIA 94901

P: 14155066700.0

CEO: Jean-Jacques Bienaime

Employees: 3082

Website: https://www.biomarin.com/

BMRN News

News Image6 days ago - The Motley Fool4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.

News Image8 days ago - BioMarin Pharmaceutical Inc.BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

News Image14 days ago - Market News VideoFirst Week of November 17th Options Trading For BioMarin Pharmaceutical (BMRN)
News Image14 days ago - BioMarin Pharmaceutical Inc.BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

News Image14 days ago - Investor's Business DailyHave Million-Dollar Gene Therapies Finally Reached An Inflection Point?

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

News Image18 days ago - BioMarin Pharmaceutical Inc.BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will...

BMRN Twits

Here you can normally see the latest stock twits on BMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example